14Jul/23
The Mechanism of CD11b Agonists in Exerting Anti-tumor Immune Response Has Been Unveiled
Using human tissue from a phase 1 clinical trial, researchers have demonstrated that treatment with GB1275, an oral small-molecule CD11b agonist, can activate the STING and STAT1 signaling pathways in human tumor-associatedRead More…